


Evaluation of a Drug Safety Algorithm for the Detection of Triple Whammy prescriptions in inpatients at risks of acute Kidney Injury


Jana Schelshorn, [Hendrike Dahmke](#), Ricco Fiumefreddo, Philipp Schuetz,
Ali Reza Salili, Francisco Cabrera, Carla Meyer-Masseti, Claudia Zaugg

GSASA Kongress 2022, 9.11.2022





TRIPLE WHAMMY



- Increases risk of Acute Kidney Injury (AKI) by 31%¹

¹Lapi F et al. *BMJ*. Jan 08 2013;346:e8525. doi:10.1136/bmj.e8525




MULTI-AGENTEN SYSTEM

TRIPLE WHAMMY ALGORITHM

- **Alert 1:** Triple Whammy and $\text{eGFR} < 30 \text{ mL/min/1.73m}^2$
- **Alert 2:** Triple Whammy and eGFR between $30\text{-}60 \text{ mL/min/1.73m}^2$
- **Alert 3:** Triple Whammy and $\text{age} \geq 75 \text{ years}$
- **Alert 4:** Triple Whammy without recent creatinine-measurements

INTERVENTIONS

- Stop NSAIDs or low dose/short duration
- Frequent measurements of creatinine (2x weekly)



Aim: Evaluation of algorithm

Clinical Pharmacists

Acceptable alert burden?
Sensitivity and Specificity?

Alerts 2021

Physicians

Acceptance Rate?
Satisfaction with algorithm?

Semi-structured Interviews

Patients

Detection of patients at risk?
Influence on kidney function?

Patients with Triple Whammy 2021



Clinical Pharmacists

- 333 alerts in 2021 for 210 patients*
- 254 alerts were processed by clinical pharmacists
- 110 (43.3%) messages were sent to physicians

	Detection necessary	Detection unnecessary	total
Alert	144	66	210
No alert	19	21'097	21'116
total	163	21'163	21'326


Sensitivity
88.3%

Specificity
99.7%

*Excluding patients who received error messages



Physicians



Triple Whammy and..

Alert 1: eGFR < 30 ml/min/1.73m²

Alert 2: eGFR between 30-60 ml/min/1.73m²

Alert 3: age ≥ 75 years

Alert 4: No recent creatinine-measurements

- Overall acceptance rate 77.7% (73 von 94)
- Acceptance rate varies and increases with priority

INTERVIEWS WITH PHYSICIANS

25%

3 out of 12



Know about the risk
of Triple Whammy
prescription

100%

11 out of 11



Consider the
algorithm helpful
and useful

80%

8 out of 10



Will avoid a Triple
Whammy prescription in
the future



PATIENTS

- In 2021 we identified 290 Triple Whammy prescriptions in 21'326 patients (1.4%)
- 19 patients had an accepted intervention and never received a Triple Whammy
- 17 patients had an AKI* under Triple Whammy prescription
 - 15 patients received an alert
 - 2 Patients did not (Age 60 and 65 and normal eGFR at baseline)



Amount of Triple Whammy Alerts is reasonable, pharmacists can manage the number well.

High specificity and sensitivity achieved, no "alert fatigue" detected



High acceptance rates, physicians are satisfied with the algorithm

15/17 Patients with AKI under Triple Whammy detected



MERCI!

Masterarbeit: Jana Schelshorn

Betreuung: Claudia Zaugg, Carla Meyer-Massetti



Entwicklung Algorithmus: Francisco Cabrera, Ali Reza Salili, Claudia Zaugg,
Ricco Fiumefreddo, Philipp Schuetz


CREDITS: This presentation template was created by **Slidesgo**, including icons by **Flaticon**, and infographics & images by **Freepik**.

Please keep this slide for attribution.

Outlook

- Implementation of dynamic kidney injury
- Adjust age as a trigger
- Discuss pausing-behavior amongst pharmacists
- Educate physicians about Triple Whammy
- Demonstrate an impact on patient safety with another study design





Age	
median [years]	77
.25 quartile [years]	67
.75 quartile [years]	83
18-34 years [number of patients]	0.5% (1)
35-54 years [number of patients]	8.3% (18)
55-74 years [number of patients]	31.5% (68)
75-84 years [number of patients]	40.3% (87)
>85 years [number of patients]	19.4% (42)
Sex [number of patients]	
female	51.9% (112)
male	48.1% (104)
Medication	
prescribed drugs [number of drugs]	21 ± 8
nephrotoxic medication [number of patients]	14.8% (32)
creatinine falsifiers [number of patients]	3.2% (7)
Duration Of Hospitalisation	
mean ± standard deviation [d]	7.1 ± 6.5
Hospital Ward [number of patients]	
surgery	35.6% (77)
orthopaedics	25.9% (56)
neurology	22.7% (49)
gynaecology	7.4% (16)
internal medicine	6.5% (14)
emergency	0.9% (2)
others	0.9% (2)
Amount Of Alerts [number of patients]	
1	66.20% (143)
2	20.37% (44)
3	6.94% (15)
4	3.24% (7)
5	1.85% (4)
6	0.93% (2)
7	0.46% (1)
eGFR Before Alert	
mean ± standard deviation [ml/min/1.73m ²]	52 ± 22

hospital ward	included wards
internal medicine	general internal medicine, angiology, dermatology, endocrinology, gastroenterology, oncology, infectiology, cardiology, nephrology, pneumology and rheumatology
surgery	plastic surgery, vascular surgery, ophthalmic clinic, otolaryngology, neurosurgery and urology
neurology	neurology
orthopaedics	orthopaedics wards and traumatology
gynaecology	breast centre, obstetrics ward and gynaecology
emergency	emergency

drug	ATC-Code
Amphotericin B	J02AA01
Ciclosporin	L04AD01
Tacrolimus	L04AD02
Vancomycin	J01XA01
Gentamicin	J01GB03
Tobramycin	J01GB01
Cidofovir	J05AB12
Aciclovir	J05AB01
Foscarnet	J05AD01
Ganciclovir	J05AB06
Adefovir	J05AF08
Quinine	M09AA* P01BC*
Bisphosphonates	M05BA* M05BB*
iodinated contrast media	V08A*
Digoxin	C01AA*
Aliskiren	C09XA02/53/52/54
Enoxaparin	B01AB05
Metformin	A10BA02, A10BD17/13/16/15/20/23/22/18/11/26/05/14/03/10/07/02/08/27/25
Lithium	N05AN01
Cisplatin	L01XA01
Carmustine	L01AD01
Semustine	L01AD03
Gemcitabine	L01BC05
Interferons	L03AB*
Methotrexate	L01BA01 L04AX03
Mitomycin	L01DC03

Drug	ATC-Codes	amount	percentage
Non-Steroidal Anti-Inflammatory Drugs (total = 346)			
Ibuprofen	M01AE01	184	53.2%
Diclofenac	M01AB05	98	28.3%
Acemetacin	M01AB11	19	5.5%
Etodolac	M01AB08	11	3.2%
Celecoxib	M01AH01	11	3.2%
Naproxen	M01AE02/52	11	3.2%
Etoricoxib	M01AH05	8	2.3%
Mefenamic Acid	M01AG01	2	0.6%
Ketorolac	M01AB15	1	0.3%
Nimesulide	M01AX17	1	0.3%
Diuretics (total = 282)			
Torsemide	C03CA04	157	55.7%
Hydrochlorothiazide	C03AA03/EA01	46	16.3%
Furosemide	C03CA01	44	15.6%
Spironolactone	C03DA01	21	7.4%
Indapamide	C03BA11	9	3.2%
Metolazone	C03BA08	3	1.1%
Chlortalidone	C03BA04	2	0.7%
Angiotensin-Converting Enzyme Inhibitor or Sartan (total = 382)			
Perindopril	C09AA04/BA04/BX01	91	23.8%
Lisinopril	C09AA03/BA03	85	22.3%
Valsartan	C09DA03/DB01/CA03/DX01/DX04	64	16.8%
Candesartan	C09DA06/CA06	53	13.9%
Olmesartan	C09DA08/CA08/DB02/DX03	30	7.9%
Irbesartan	C09DA04/CA04	19	5%
Losartan	C09DA01/CA01	17	4.5%
Telmisartan	C09DA07/DB04	9	2.4%
Ramipril	C09AA05	9	2.4%
Azilsartan	C09CA09	3	0.8%
Enalapril	C09AA02/BB02	2	0.6%

